U.S. patent application number 10/753367 was filed with the patent office on 2004-07-22 for quinolonecarboxylic acid derivatives.
This patent application is currently assigned to DAIICHI PHARMACEUTICAL CO., LTD.. Invention is credited to Hayakawa, Isao, Itoh, Masao, Kawakami, Katsuhiro, Miyauchi, Rie, Ohtani, Tsuyoshi, Sekiguchi, Masayasu, Suzuki, Tetsuya, Takahashi, Hisashi, Takemura, Makoto.
Application Number | 20040142957 10/753367 |
Document ID | / |
Family ID | 26589134 |
Filed Date | 2004-07-22 |
United States Patent
Application |
20040142957 |
Kind Code |
A1 |
Takemura, Makoto ; et
al. |
July 22, 2004 |
Quinolonecarboxylic acid derivatives
Abstract
(-)-7-[(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic acid.1HCl.1H.sub.2O and antibacterial compositions containing
this compound. The compound of the present invention exhibits not
only excellent antibacterial activity and safety, but also
remarkable stability against light and humidity, and is thus useful
as an antibacterial agent.
Inventors: |
Takemura, Makoto; (Tokyo,
JP) ; Takahashi, Hisashi; (Tokyo, JP) ;
Kawakami, Katsuhiro; (Tokyo, JP) ; Itoh, Masao;
(Tokyo, JP) ; Suzuki, Tetsuya; (Tokyo, JP)
; Ohtani, Tsuyoshi; (Tokyo, JP) ; Sekiguchi,
Masayasu; (Tokyo, JP) ; Miyauchi, Rie; (Tokyo,
JP) ; Hayakawa, Isao; (Tokyo, JP) |
Correspondence
Address: |
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON
DC
20037
US
|
Assignee: |
DAIICHI PHARMACEUTICAL CO.,
LTD.
|
Family ID: |
26589134 |
Appl. No.: |
10/753367 |
Filed: |
January 9, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10753367 |
Jan 9, 2004 |
|
|
|
10275972 |
Mar 31, 2003 |
|
|
|
10275972 |
Mar 31, 2003 |
|
|
|
PCT/JP01/02761 |
Mar 30, 2001 |
|
|
|
Current U.S.
Class: |
514/278 ;
546/15 |
Current CPC
Class: |
A61P 31/04 20180101;
C07D 401/04 20130101; A61K 31/4709 20130101 |
Class at
Publication: |
514/278 ;
546/015 |
International
Class: |
A61K 031/4747; C07D
471/12 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 31, 2000 |
JP |
2000-097690 |
Sep 7, 2000 |
JP |
2000-271231 |
Claims
1. A compound represented by the following formula (1). 12
2. A compound as claimed in claim 1, which assumes crystals
exhibiting characteristic peaks in the vicinity of angles of
diffraction (2.theta.) of 6.9, 10.5, 14.4, 23.1, 26.9, and
27.8(.degree.) when subjected to powder X-ray diffractometry.
3. An antibacterial composition containing a compound represented
by the following formula (1a), an acid addition salt of the
compound, or a hydrate of the formula (1a) compound or the acid
addition salt. 13
4. The antibacterial composition as claimed in claim 3, containing
an acid addition salt of a compound represented by formula (1a), or
a hydrate of the acid addition salt.
5. The antibacterial composition as claimed in claim 4, wherein the
acid addition salt is a hydrochloric acid salt.
6. An antibacterial composition containing a compound represented
by the following formula (1). 14
7. An antibacterial composition as claimed in claim 4, wherein the
compound of formula (1) assumes crystals exhibiting characteristic
peaks in the vicinity of angles of diffraction (2.theta.) of 6.9,
10.5, 14.4, 23.1, 26.9, and 27.8(.degree.) when subjected to powder
X-ray diffractometry.
8. Use, in the manufacture of a drug for the treatment of
infectious diseases, of a compound represented by the following
formula (1a), an acid addition salt of the compound, or a hydrate
of the formula (1a) compound or the acid addition salt. 15
9. The use as claimed in claim 8, which employs an acid addition
salt of the compound represented by formula (1a), or a hydrate of
the acid addition salt.
10. The use as claimed in claim 9, wherein the acid addition salt
is a hydrochloric acid salt.
11. Use, in the manufacture of a drug for the treatment of
infectious diseases, of a compound represented by the following
formula (1). 16
12. The use as claimed in claim 11, wherein the compound of formula
(1) assumes crystals exhibiting characteristic peaks in the
vicinity of angles of diffraction (2.theta.) of 6.9, 10.5, 14.4,
23.1, 26.9, and 27.8(.degree.) when subjected to powder X-ray
diffractometry.
13. A method for the treatment of infectious diseases, which is
characterized by administering an effective amount of a compound
represented by the following formula (1a), an acid addition salt of
the compound, or a hydrate of the formula (1a) compound or the acid
addition salt. 17
14. The method as claimed in claim 13, which employs an acid
additional salt of the compound represented by formula (1a), or a
hydrate of the acid addition salt.
15. The method as claimed in claim 14, wherein the acid additional
salt is a hydrochloric acid salt.
16. A method for the treatment of infectious diseases, which is
characterized by administering an effect amount of a compound
represented by the following formula (1). 18
17. The method as claimed in claim 16, wherein the compound of
formula (1) assumes crystals exhibiting characteristic peaks in the
vicinity of angles of diffraction (2.theta.) of 6.9, 10.5, 14.4,
23.1, 26.9, and 27.8(.degree.) when subjected to powder X-ray
diffractometry.
Description
BACKGROUND OF THE INVENTION
[0001] 1. Field of the Invention
[0002] The present invention relates to optically active
quinolonecarboxylic acid derivatives which exhibit high
antibacterial activity and safety and have remarkable stability,
and to an antibacterial composition containing such a
derivative.
[0003] 2. Related Art
[0004] Quinolonecarboxylic acid derivatives are a class known as
synthetic antibacterial agents. Particularly, compounds of the
following formula (I) having a 1,2-cis-2-halogenocyclopropyl group
on the nitrogen atom at the 1-position of the quinolone skeletone
exhibit strong antibacterial activity and safety, and thus are
known to be useful as pharmaceutical agents (Japanese patent No.
2714597 and 2917010); 1
[0005] wherein R.sup.1 is an amino group, a methylamino group, a
hydroxyl group, a thiol group, or a hydrogen atom; and R.sup.2 is a
substituent selected from the group consisting of the following
groups: 2
[0006] (wherein R.sup.3, R.sup.4, R.sup.5, and R.sup.6 each
independently represents a hydrogen atom or a C1-C6 alkyl group,
R.sup.10 and R.sup.11 each independently represents a hydrogen atom
or a C1-C6 alkyl group, R.sup.12 and R.sup.13 each independently
represents a hydrogen atom or a C1-C6 alkyl group or R.sup.12 and
R.sup.13 may form a polymethylene chain of from 2 to 5 carbon
atoms), or a 3-hydroxypyrrolidinyl group which may have a C1-C6
alkyl group; A represents C--X.sup.3 or a nitrogen atom: X.sup.1
and X.sup.2 each independently represents a halogen atom; X.sup.3
represents a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy
group, trifluoromethyl group, or a hydrogen atom; and Z represents
a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxyalkyl group, a
phenylalkyl group of C1-C6 alkyl, a phenyl group, an acetoxymethyl
group, a pivaloyloxymethyl group, an ethoxycarbonyloxy group, a
chorine group, a dimethylaminoethyl group, a 5-indanyl group, a
phthalidinyl group, a 5-substituted-2-oxo-1,3-dioxol-4-ylmethyl
group, or a 3-acetoxy-2-oxobutyl group; with the case in which
R.sup.2 is a 3-aminopyrrolidinyl group and R.sup.1 and X.sup.3 are
hydrogen atoms being excluded.
[0007] A variety of fluoroquinolone synthetic antibacterial agents
have been developed to provide clinical drugs for chemotherapy
which are effective in the treatment of a broad range of systemic
infectious diseases. Nevertheless, demands still exist for
compounds which exhibit higher antibacterial activity, which are
safer than the previous compounds, and in addition, which are
endowed with excellent stability against light and humidity.
SUMMARY OF THE INVENTION
[0008] In view of the foregoing, the present inventors, focusing on
N.sub.1-(1,2-cis-2-fluorocyclopropyl)-substituted
pyrrolidonecarboxylic acids disclosed in the aforementioned
Japanese Patent No. 2714597, have performed further research and
have found that a monohydrochloride.monohy- drate of compound No.
41 disclosed in Japanese Patent No. 2714597--but the disclosure
being limited only to the chemical formula of its free form,
particularly,
(-)-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-- [(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinec-
arboxylic acid (hereinafter referred to as compound (1a); compound
(1a) corresponds to a free form and is represented by the following
formula (1a))--exhibits not only excellent antibacterial activity
and safety, but also exceptionally excellent stability against
light and humidity as compared with other acid-adduct salts, and is
thus useful as an antibacterial agent. The present invention has
been accomplished on the basis of these findings.
[0009] Accordingly, the present invention provides a compound
represented by the following formula (1): 3
[0010] which is
(-)-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1- -[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinoline-
carboxylic acid monohydrochloride monohydrate (hereinafter referred
to as compound (1); compound (1) is a monohydrochloride-monohydrate
of compound (1a)), and antibacterial agents containing the compound
(1).
[0011] The present invention also provides an antibacterial agent
containing a compound represented by the following formula (1a), an
acid-adduct salt thereof, or a hydrate of the following formula
(1a) compound or the acid-adduct salt. 4
[0012] The present invention further provides use of the
above-described compound of formula (1a), an acid-addition salt
thereof, or a hydrate of the formula (1a) compound or the
acid-addition salt in the manufacture of a drug for the treatment
of infectious diseases.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 shows a powder X-ray diffraction spectrum of compound
(1).
[0014] FIG. 2 shows an infrared absorption spectrum of compound
(1).
[0015] FIG. 3 is a graph showing the weight change of compound (1)
under 5-95% RH.
DETAILED DESCRIPTION OF THE INVENTION AND
PREFERRED EMBODIMENTS
[0016] Compound (1a) can be produced from a compound (2) at high
yield in accordance with the following reaction scheme. Briefly, an
amine compound (3) is reacted with compound (2) (note: both of
these compounds can be obtained through the method described in
Japanese Patent No. 2714597), and treatment of the resultant
compound (1b) with a protic solvent yields compound (1a).
Accordingly, compound (1b) is a useful synthetic intermediate in
the production of compound (1a). 5
[0017] With regard to the reaction conditions under which compound
(1b) is produced from compound (2), for example, a solution of
dihydrochloride of amine (3) and triethylamine in dimethylsulfoxide
is stirred (ordinary, for at most 2 to 3 hours is enough) at room
temperature a solution of, and thereafter, compound (2) is added
thereto and are reacted at room temperature for 10 minutes to
several hours. In this reaction, instead of the dihydrochloride of
amine (3), a corresponding free base (3) or a salt of any other
type may be used. The salt of any other type may be, for example,
monohydrochloride, or a mono- or di-salt ere, "mono-" and "di-" are
both with respect to amine (3) of organic or inorganic acid (other
than HCl). Alternatively, the salt may be in the form of a hydrate
or a solvate. Examples of the organic or inorganic acid suitable
for acid-addudct salt (other than HCl) include sulfuric acid,
nitric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid,
p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid,
trichloroacetic acid, acetic acid, formic acid, maleic acid, and
fumaric acid. Examples of the reaction solvent in addition to
dimethylsulfoxide include N,N-dimethylformamide,
N,N-dimethylacetamide, and N-methylpyrrolidone. In the
above-mentioned example in which triethylamine is used, when a free
base of amine (3) is employed, the amount of triethylamine is
preferably one equivalent or more, more preferably two equivalents
or more. When a salt of amine (3) is employed, the amount of
triethylamine is preferably equal to or more than a total of the
equivalent required for rendering the salt into a free base and the
equivalent required for capturing hydrogen fluoride generated from
the reaction. Instead of triethylamine, any other organic or
inorganic bases, such as 4-(dimethylamino)pyridine or potassium
carbonate, may be used.
[0018] The production step of compound (1a) from compound (1b) may
be performed by, for example, dissolving compound (1b) in aqueous
ethanol, adding triethylamine to the resultant mixture, followed by
refluxing for a few hours. The aqueous ethanol may be replaced by
another protic solvent, such as aqueous isopropanol. The protic
solvents miscible with water are suitable for this process, and
these which can at least dissolve compound (1b) when heated is
preferable. Note that triethylamine is not necessarily added.
[0019] Compound (1a) may also be produced from a compound (2) at
high yield in accordance with the following reaction scheme.
Briefly, amine compound (5) is reacted with compound (2), to
thereby obtain a carboxylic compound (7), and thereafter the
protective group for the amino group is removed. 6
[0020] (wherein R represents an alkoxycarbonyl group, an
aralkyloxycarbonyl group, an acyl group, an alkyl group, an aralkyl
group, an alkoxyalkyl group (all of these may have substituent(s)),
or a substituted silyl group). Accordingly, compounds (6) and (7)
are useful as synthetic intermediates in the production of compound
(1a).
[0021] In compound (6), R serves as a protective group for an amino
group, and is an alkoxycarbonyl group which may have
substituent(s), an aralkyloxycarbonyl group which may have
substituent(s), an acyl group which may have substituent(s), an
alkyl group which may have substituent(s), an aralkyl group which
may have substituent(s), an alkoxyalkyl group which may have
substituent(s), or a substituted silyl group. Of these species, R
is preferably alkoxycarbonyl group, an aralkyloxycarbonyl group, an
acyl group, or a silyl group, with alkoxycarbonyl and
aralkyloxycarbonyl being more preferred. Specific examples of the
alkoxycarbonyl group which may have substituent(s) include a
tert-butoxycarbonyl group (Boc) and a 2,2,2-trichloroethoxycarb-
onyl group, wherein the tert-butoxycarbonyl group is preferred.
Specific examples of the aralkyloxycarbonyl which may have
substituent(s) group include a benzyloxycarbonyl group, a
p-methoxybenzyloxycarbonyl group, and a p-nitrobenzyloxycarbonyl
group, wherein the p-methoxybenzyloxycarbo- nyl group and the
p-nitrobenzyloxycarbonyl group are preferred. Specific examples of
the acyl group which may have substituent(s) include an acetyl
group, a methoxyacetyl group, a trifluoroacetyl group, a
chloroacetyl group, a pyvaloyl group, a formyl group, and a benzoyl
group. Of these species, a trifluoroacetyl group, a chloroacetyl
group, a pyvaloyl group, and a formyl group are preferred. Specific
examples of the alkyl group which may have substituent(s) include a
tert-butyl group. Examples of the aralkyl group which may have
substituent(s) include a benzyl group, a p-nitrobenzyl group,
p-methoxybenzyl group, and a triphenylmethyl group, with the
p-methoxybenzyl group and triphenylmethyl group being preferred.
Examples of the alkoxyalkyl group which may have substituent(s)
include a methoxymethyl group, a tert-butoxymethyl group, a
2,2,2-trichloroethoxymethyl group, and a tetrahydrofuranyl group,
with the tert-butoxymethyl group and tetrahydrofuranyl group being
preferred. Examples of the substituted silyl group include a
trimethylsilyl group, an isopropyldimethylsilyl group, a
tert-butyldimethylsilyl group, a tribenzylsilyl group, and a
tert-butyldiphenylsilyl group, with the isopropyldimethylsilyl
group, a tert-butyldimethylsilyl group being preferred.
[0022] However, R is not limited only to the above-listed species,
and any group which is ordinarily used for the protection of an
amino group is suitable for the present invention and the
protective group selected from the group consisting of
alkoxycarbonyl groups, aralkyloxycarbonyl groups, acyl groups,
alkyl groups, aralkyl groups, alkoxyalkyl groups, and silyl groups
may serve as R.
[0023] With regard to the reaction conditions under which compound
(6) is produced, for example, an amine (5) may be used to cause a
reaction in dimethylsulfoxide in the presence of trimethylamine at
room temperature for several hours to one day. Amine (5) may be in
the form of a free base, or a salt of an organic or inorganic acid.
Preferably, amine (5) is used in an mount of one equivalent or
more. When a free base of amine (5) is used, a required amount of
triethylamine is one or more equivalents, more preferably two or
more equivalents. Alternatively, when a salt of amine (5) is
employed, the amount of triethylamine is preferably equal to or
more than a total of the equivalent required for rendering the salt
into a free base, and further equivalent required for capturing
hydrogen fluoride generated from the reaction. Examples of salts of
amine (5) include salts of organic or inorganic acid, such as
hydrochloric acid, sulfuric acid, nitric acid, hydrofluoric acid,
hydrobromic acid, hydroiodic acid, p-toluenesulfonic acid,
methanesulfonic acid, trifluoroacetic acid, trichloroacetic acid,
acetic acid, formic acid, maleic acid, and fumaric acid. These
salts may be in a form of hydrates or solvates. Examples of the
reaction solvent in addition to dimethylsulfoxide include
N,N-dimethylformamide, N,N-dimethylacetamide, and
N-methylpyrrolidone. In the above-mentioned example in which
triethylamine is used, the triethylamine may be replaced by any one
of organic or inorganic bases, such as 4-(dimethylamino)pyridine or
potassium carbonate.
[0024] Conversion of compound (6) to compound (7) may be performed
by, for example, dissolving compound (6) in aqueous ethanol, adding
triethylamine to the resultant mixture, followed by refluxing for a
few hours. The aqueous ethanol may be replaced by another protonic
solvent, such as aqueous isopropanol. The protic solvents miscible
with water are suitable for this process, and these which can at
least dissolve compound (1b) when heated is preferable. Note that
triethylamine is not necessarily added.
[0025] In the step of producing compound (1a) from compound (7),
the conditions under which the protective group R is removed must
conform with the properties of the protective group R. Typical
exemplary cases are as follows. When R is a tertbutoxycarbonyl
group (Boc), deprotection may be carried out through treatment with
an organic or inorganic acid such as hydrochloric acid, sulfuric
acid, nitric acid, hydrofluoric acid, hydrobromic acid, hydroiodic
acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic
acid, trichloroacetic acid, acetic acid, or formic acid. The
temperature at which deprotection is carried out is suitably chosen
from the range of -30 to 100.degree. C., in accordance with the
type and concentration of the acid employed and with the property
of the solvent. Similarly, deprotection may be carried out for a
p-methoxybenzyloxycarbonyl group, an acetyl group, a pyvaloyl
group, a methoxyacetyl group, a formyl group, a tert-butyl group, a
methoxymethyl group, a tert-butoxymethyl group, a tetrahydrofuranyl
group, a trimethylsilyl group, a triphenylmethyl group, or from
similar groups through treatment with an acid that is suitably
chosen from among hydrochloric acid, sulfuric acid, nitric acid,
hydrofluoric acid, hydrobromic acid, hydroiodic acid,
p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid,
and trichloroacetic acid. A 2,2,2-trichloroethoxycarbonyl group and
a 2,2,2-trichloroethoxymethyl group may be removed by using a
combination of zinc and an acid (HCl or acetic acid). Deprotection
of a benzyloxycarbonyl group, a p-methoxybenzyloxycarbonyl group, a
p-nitrobenzyloxycarbonyl group, a benzyl group, a p-nitrobenzyl
group, a p-methoxybenzyl group, or a triphenylmethyl group can be
carried out through catalytic reduction. Acyl groups such as an
acetyl group, a methoxyacetyl group, a trifluoroacetyl group, a
chloroacetyl group, a pyvaloyl group, a formyl group, and a benzoyl
group may be removed through treatment with an acid such as HCl or
an alkali such as NaOH. Silyl groups such as a trimethylsilyl
group, an isopropyldimethylsilyl group, a tert-butyldimethylsilyl
group, a tribenzylsilyl group, and a tert-butyldiphenylsilyl group
may be removed by use of an acid or fluoride ions. In this case,
example of the acid include acetic acid, hydrochloric acid, and
hydrofluoric acid, and a suitable acid must be chosen so as to be
in conformity with the properties of the silyl group. As for the
source of the fluoride ions, tetrabutylammonium fluoride may be
used. A chloroacetyl group can be removed by use of thiourea.
Details of the conditions under which deprotection is carried out
are ordinary ones and not particularly limited.
[0026] With reference to compound (6), when R is a
tert-butoxycarbonyl group or a similar group which can be removed
by an acid, compound (1a) can be obtained through direct treatment
of compound (6) with an organic or inorganic acid such as
hydrochloric acid, sulfuric acid, nitric acid, hydrofluoric acid,
hydrobromic acid, hydroiodic acid, p-toluenesulfonic acid,
methanesulfonic acid, trifluoroacetic acid, or trichloroacetic
acid.
[0027] In the above-described two production methods, compound (1a)
may be obtained in a free form or as a salt. Examples of the salt
include a salt of an inorganic or organic acid, such as
hydrochloric acid, sulfuric acid, nitric acid, hydrofluoric acid,
hydrobromic acid, hydroiodic acid, p-toluenesulfonic acid,
methanesulfonic acid, trifluoroacetic acid, trichloroacetic acid,
acetic acid, maleic acid, or fumaric acid; and a salt of an alkali
or alkaline earth metal such as sodium, potassium, calcium, or
lithium. In either case of compound (1a) being in its free form or
a salt, the compound (1a) may be obtained in the form of a solvate.
Examples of the solvate include those formed with water, ethanol,
propanol, acetonitrole, or acetone; and hydrates which may be
formed through absorption of moisture in air.
[0028] The compound (2) which is used in the aforementioned two
reaction schemes for producing compound (1a) may be prepared
through the following reaction path. 7
[0029] In the above scheme, in order to produce compound (2) from
compound (12), an ether complex of boron trifluoride may be used.
Alternatively, compound (2) may be obtained without obtaining
compound (12) but by treating compound (11) with tetrafluoroboric
acid as shown below. 8
[0030] Conversion from compound (1a) to compound (1) can be carried
out by, for example, suspending compound (1a) in an alcoholic
solvent such as 2-propanol or ethanol, dissolving the suspension by
the addition of HCl, and subsequently crystallizing from an
alcoholic solvent such as 2-propanol or ethanol.
[0031] The thus-obtained compounds (1a), their acid-addition salts,
or salts of the compounds (1a), in particular compounds (1), which
are monohydrochlorides.monohydrates of compounds (1a), exhibit more
excellent antibacterial activity and higher stability against light
and humidity than, let alone other compounds, compound Nos. 9a, 9b,
13b, 18a, 18b, 26bb, 26aa, 26ba, 26ab, 31a, 31b, 34b, 54b, 56b,
52bb, or 85bb disclosed in Japanese Patent No. 2714597 or 2917010,
and are thus useful as antibacterial agents. Preferred
acid-addition salts of compounds (1a) applicable for antibacterial
agents are hydrochloric acid salts. Among the mentioned compounds
(1a), their acid-addition salts, and salts of the compounds (1a) or
the acid-addition salts, compounds (1) are particularly
preferred.
[0032] More preferred compounds (1); i.e.,
monohydrochlorides.monohydrates of compounds (1a), are those
exhibiting characteristic peaks in the vicinity of angles of
diffraction (2.theta.) of 6.9, 10.5, 14.4, 23.1, 26.9, and
27.8(.degree.) when subjected to powder X-ray diffractometry (see
FIG. 1). The compounds (1) satisfying the above conditions do not
absorb or desorb moisture under humidity conditions of 5 to 95% RH,
and thus has excellent hygroscopic stability.
[0033] The compounds of the present invention, exhibiting strong
antibacterial activity and excellent stability against light and
humidity, are useful as pharmaceuticals for the treatment of
humans, animals, and fish.
[0034] When the compounds of the present invention are used as
pharmaceuticals for humans, the daily dose for an adult is from 50
mg to 1 g, preferably from 100 mg to 300 mg. When the compounds are
administered to animals, the dose may vary depending on the purpose
of administration (therapeutic or preventive), the species and size
of the animal to be treated, the nature of the pathogen that
infected the animal, and the severity of the pathological
condition. However, the daily dose is typically from 1 mg to 200
mg, preferably from 5 mg to 100 mg, per kg of the body weight of
the animal. This dose is administered once a day or 2-4 divided
times a day. The daily dose may exceed the above-mentioned
ranges.
[0035] Antibacterial compositions containing the aforementioned
compounds of the present invention can be formulated in a variety
of formulations through any ordinary methods in accordance with the
manner of the administration. Examples of the peroral form of the
antibacterial formulations containing the compound of the present
invention as an active ingredient include tablets, powders,
granules, capsules, solutions, syrups, elixirs, and oil-based or
water-based suspensions.
[0036] Injections may contain a stabilizer, a preservative, or a
solubilizing agent. Therefore, a solution which may contain any of
these auxiliary agents may be placed in a container, and a solid
preparation may be formulated through, for example, freeze-drying,
thereby yielding a pharmaceutical product for bed-side preparation.
Moreover, one dose or a plurality of doses may be contained in a
single container.
[0037] When the composition of the present invention is formulated
into external agents, examples of the external agents include
solutions, suspensions, emulsions, ointments, gels, creams,
lotions, and sprays.
[0038] Solid preparations may contain, in addition to the compound
of the present invention, pharmaceutically acceptable additives
including fillers, volume-increasing agents, binders,
disintegrants, dissolution accelerators, wetting agents, and
lublicants, as needed.
[0039] Examples of liquid preparations include solutions,
suspensions, and emulsions. Liquid preparations optionally contain
suspension aids and emulsifiers as additives therefor.
EXAMPLES
[0040] The present invention will be described in more detail by
way of examples, which should not be construed as limiting the
invention thereto.
Referential Example 1
[0041] Ethyl
3-dimethylamino-2-(3-methoxy-2,4,5-trifluorobenzoyl)acrylate:
[0042] Thionyl chloride (109.4 ml; 1500 mmol) was added dropwise at
room temperature to a suspension containing 3-methoxy
2,4,5-trifluorobenzoic acid (206.1 g; 1000 mmol),
N,N-dimethylformamide (2 ml), and toluene (2000 ml). After
completion of the addition, the reaction mixture was stirred in an
oil bath at 80.degree. C. for 16 hours. The reaction mixture was
cooled, and the cooled solution was concentrated under reduced
pressure. Toluene was added to the residue, and the mixture was
concentrated again. The procedure from the toluene addition to the
concentration was repeated two more times, to thereby yield an acid
chloride.
[0043] Ethyl 3-dimethylamino acrylate (171.8 g; 1200 mmol) and
triethylamine (184.0 ml; 1320 mmol) were added to dry
tetrahydrofuran (1500 ml). To the solution, a solution of the
above-prepared acid chloride in dry tetrahydrofuran (500 ml) was
added dropwise under ice cooling. After completion of the addition,
the reaction suspension was refluxed for 5 hours, followed by
cooling. The cooled reaction mixture was concentrated under reduced
pressure, and water (1500 ml) and dichloromethane (1500 ml) were
added to the residue, followed by stirring. The dichloromethane
layer was collected, and the aqueous layer was extracted with
dichloromethane (1000 ml). The combined dichloromethane layer was
washed with saturated brine (1500 ml), and dried over anhydrous
sodium sulfate, followed by filtration. The filtrate was
concentrated under reduced pressure, and the residue was subjected
to silica gel column chromatography. Fractions eluted with
n-hexane/ethyl acetate (1:1) were concentrated, followed by drying
under reduced pressure, to thereby yield 270.3 g of the title
compound as yellowish white creamy matter (yield: 81.6%).
[0044] .sup.1H-NMR(400 MHz, CDCl.sub.3).delta.: 1.02(3H, t, J=7.08
Hz), 2.88(3H, br), 3.32(3H, br), 4.00(2H, q, J=7.08 Hz),
7.09-7.13(1H, m), 7.83(1H, s).
Referential Example 2
[0045] Ethyl 3-[(1R,
2S)-2-fluoro-1-cyclopropylamino]-2-(3-methoxy-2,4,5-t-
rifluorobenzoyl)acrylate:
[0046] Ethyl
3-dimethylamino-2-(3-methoxy-2,4,5-trifluorobenzoyl)acrylate (260.5
g; 786.3 mmol) was dissolved in dichloromethane (2200 ml), and (1R,
2S)-2-fluoro-1-cyclopropylamine p-toluene sulfonate (223.6 g; 904.2
mmol) was added to the solution. The resultant suspension was
cooled to -15.degree. C., and a solution of triethylamine (138.6
ml; 994.6 mmol) in dichloromethane (300 ml) was added dropwise to
the suspension over 40 minutes while being stirred. After
completion of the addition, the temperature was maintained for 1
hour, and then the suspension was cooled on ice for 1 hour,
followed by stirring at room temperature for 14 hours.
Dichloromethane (1000 ml) and water (2000 ml) were added to the
reaction mixture, and the dichloromethane layer was collected. The
aqueous layer was extracted with dichloromethane (500 ml), and the
combined organic layer was washed with saturated brine (1000 ml),
followed by drying over anhydrous sodium sulfate. The mixture was
filtered, and the filtrate was concentrated under reduced pressure,
to thereby yield 227.5 g of the title compound as yellow creamy
matter (yield: 97.7%). The reaction product was a mixture of
geometrical isomers (E and Z isomers). The product was used for the
subsequent reaction without further purification.
[0047] .sup.1H-NMR(400 MHz, CDCl.sub.3).delta.: 0.97, 1.09 (total
3H, each t, J=7.08 Hz), 1.21-1.37 (2H, m), 2.90-2.99 (1H, m), 4.01
(3H, s), 4.03, 4.06(total 2H, each q, J=7.08 Hz), 4.73 (1H, dm,
J=63.72 Hz), 6.86-6.92, 6.98-7.04 (total 1H, each m), 8.16, 8.23
(total 1H, each d, J=13.67 Hz)
Referential Example 3
[0048] Ethyl 6,7-difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro--
8-methoxy-4-oxo-3-quinoline Carboxylate:
[0049] The above-synthesized crude ethyl 3-[(1R,
2S)-2-fluoro-1-cyclopropy-
lamino]-2-(3-methoxy-2,4,5-trifluorobenzoyl) acrylate (276.2 g;
764.5 mmol) was dissolved in dry N,N-dimethylformamide (2000 ml),
and potassium carbonate (317.0 g; 2.293 mmol) was suspended in the
solution under ice cooling, followed by stirring for 72 hours at
room temperature. Hydrochloric acid (2N) was added dropwise slowly
to the reaction mixture so as to adjust the pH of the resultant
suspension to about 3 while the suspension was stirred under ice
cooling. The suspension was stirred for 30 minutes at room
temperature, and crystals precipitated were collected by
filtration. The thus-obtained crystals were sequentially washed
with an excessive amount of purified water, a small amount of cold
ethanol, and an excessive amount of diethylether, followed by
drying under reduced pressure at 70.degree. C., to thereby yield
213.4 g of the title compound as a white powder (yield: 81.8%).
[0050] .sup.1H-NMR(400 MHz, CDCl.sub.3).delta.: 1.41 (3H, t, J=7.08
Hz), 1.56-1.68(2H, m), 3.83-3.88(1H, m), 4.10(3H, d, J=2.20 Hz),
4.39(2H, q, J=7.08 Hz), 4.85(1H, dm, J=62.99 Hz), 8.05(1H, dd,
J=8.55, 10.01 Hz), 8.57(1H, d, J=1.22 Hz).
Referential Example 4
[0051] 6,7-Difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-meth-
oxy-4-oxo-3-quinolinecarboxylic Acid:
[0052] A mixture of ethyl 6,7-difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-
-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylate (120.8 g; 354.1
mmol), glacial acetic acid (210 ml), and conc. hydrochloric acid
(420 ml) was refluxed for 6 hours, followed by cooling. The cooled
reaction mixture was poured into ice/water (1500 ml) while being
stirred, and the mixture was stirred for an additional 30 minutes
at room temperature. Crystals precipitated were collected by
filtration, and the crystals were sequentially washed with an
excessive amount of purified water, ethanol (300 ml), and diethyl
ether (500 ml). The crystals were purified through
recrystallization from ethanol-acetone (also through treatment with
activated carbon and filtration), followed by drying under reduced
pressure at 70.degree. C., to thereby yield 107.0 g of the title
compound as white needles (yield: 96.5%).
[0053] .sup.1H-NMR(400 MHz, CDCl.sub.3).delta.: 1.64-1.75(2H, m),
3.97-4.00(1H, m), 4.17(3H, d, J=2.20 Hz), 4.91(1H, dm, J=63.23 Hz),
8.05(1H, dd, J=8.55, 10.01 Hz), 8.84(1H, s), 14.31(1H, s).
Referential Example 5
[0054] 6,7-Difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-meth-
oxy-4-oxo-3-quinolinecarboxylic Acid Difluoroboron Chelate:
[0055] 6,7-Difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-meth-
oxy-4-oxo-3-quinolinecarboxylic acid (90.30 g; 288.3 mmol) was
suspended in dry diethylether (1000 ml), and boron
trifluoride/diethylether complex (653 ml) was added dropwise to the
suspension under ice cooling. After completion of the addition, the
reaction suspension was stirred for 24 hours at room temperature,
and crystals precipitated were collected by filtration, followed by
washing with an excessive amount of dry diethylether. The washed
crystals were dried under reduced pressure at room temperature, to
thereby yield 96.47 g of the title compound as a white powder
(92.7%).
[0056] .sup.1H-NMR(400 MHz, CDCl.sub.3).delta.: 1.77-1.98(2H, m),
4.30(3H, d, J=2.93 Hz), 4.38-4.44(1H, m), 5.03(1H, dm, J=62.50 Hz),
8.17(1H, dd, J=8.06, 8.79 Hz), 9.14(1H, s).
Referential Example 6
[0057] 6,7-Difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-meth-
oxy-4-oxo-3-quinolinecarboxylic Acid Difluoroboron Chelate
(Alternative Synthesis Method):
[0058] A mixture of ethyl 6,7-difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-
-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylate (260 mg; 0.733
mmol) and tetrafluoro boric acid (42%: 5 ml) was stirred in an oil
bath at 90.degree. C. for 3 hours. The reaction mixture was cooled,
and an excessive amount of purified water was added to the
solution. Crystals that precipitated were collected by filtration,
and sequentially washed with purified water (excess amount) and
diethylether (excess amount). The crystals were collected by
filtration, and dried under reduced pressure at room temperature,
to thereby yield 241 mg of the title compound as a white powder
(yield: 91.1%). The .sup.1H-NMR data of the reaction product was in
agreement with the data of that synthesized in accordance with
other synthesis methods.
Example 1
[0059]
(-)-7-{(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic Acid (Compound 1a):
[0060] (7S)-7-Amino-5-azaspiro[2.4]heptane dihydrochloride (61.4 g;
0.332 mol) was dissolved in dimethylsulfoxide (800 ml), and
triethylamine (138 ml; 0.994 mol) was added to the resultant
solution under a nitrogen atmosphere at room temperature, followed
by stirring for 10 hours. 6,7-Difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4--
oxo-3-quinolinecarboxylic acid difluoroboron chelate (100 g; 0.276
mol) in powder form was slowly added to the reaction mixture,
followed by stirring for 40 hours at room temperature. The reaction
mixture was concentrated under reduced pressure, and ethanol (90%:
1000 ml) and triethylamine (20 ml) were added thereto, followed by
refluxing for 2.5 hours. The reaction mixture was left to cool, and
crystals that precipitated were collected by filtration. The
crystals were sequentially washed with ethanol and ether, followed
by drying under reduced pressure at 70.degree. C. for 16 hours, to
thereby yield 72.5 g of the title compound (as 0.5 hydrate) as a
pale yellow powder (yield: 61.4%). Solvents were removed from the
filtrate under reduced pressure, and water (2000 ml) was added to
the residue. An aqueous sodium hydroxide solution (3N) was added to
the mixture so as to adjust the pH value to 10.0 while being
stirred under ice cooling. Subsequently, an aqueous hydrochloric
acid solution (3N) was added to the mixture so as to adjust the pH
to 7.4, followed by stirring for 16 hours at room temperature.
Crystals that precipitated were collected by filtration, washed
with water, and dried under reduced pressure at 70.degree. C., to
thereby yield 19.2 g of the title compound (as 0.5 hydrate) as a
pale yellow powder (yield: 33.6%).
[0061] .sup.1H-NMR(400 MHz, 0.1N NaOD).delta.: 0.53-0.59(2H, m),
0.62-0.66(1H, m), 0.78-0.82(1H, m), 1.38-1.60(2H, m), 3.07(1H, s),
3.39(1H, dd, J=10.3, 26.0 Hz), 3.52(3H, s), 3.72(1H, d, J=10.0 Hz),
3.89-4.00(2H, m), 4.93(1H, dm, J=64.2 Hz), 7.62(1H, d, J=14.2 Hz),
8.43(1H, s).
[0062] Elementary analysis: on the basis of
C.sub.20H.sub.21F.sub.2N.sub.3- O.sub.4.0.5H.sub.2O
[0063] Calculated: C 57.97; H 5.35; N 10.14
[0064] Found: C 57.97; H 5.31; N 10.11
[0065] Specific rotation:
[.alpha.].sub.D.sup.22-25.5.degree.(c=0.832, 0.1N NaOH).
[0066] Melting point: 207-209.degree. C.
Example 2
[0067]
(-)-7-{(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic Acid Monohydrochloride Monohydrate (Compound 1):
[0068] In a 3-liter teardrop flask, crystalline
(-)-7-[(7S)-7-amino-5-azas- piro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dih-
ydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 0.5 hydrate (61.3
g; 148 mmol: calculated based on the free form: 60.0 g) was
suspended in 2-propanol (720 ml). Subsequently, hydrochloric acid
(5N: 59.2 ml; 296 mmol) was slowly added dropwise to the suspension
while being stirred under ice cooling. The thus-obtained mixture
was brought to room temperature, and distilled water (420 ml) was
added thereto, followed by stirring for 10 minutes. The mixture was
heated to 60.degree. C. in a water bath while being stirred. After
the suspension turned into a transparent solution, activated carbon
(3 g) was added thereto, and the admixture was stirred for 20
minutes at an external temperature of 80.degree. C. The activated
carbon was filtered off, and the filtrate was concentrated under
reduced pressure, followed by concentrated to driness through
evaporation. The residue was dried in a water bath at 70.degree. C.
for 1 hour by use of a vacuum pump, and 2-propanol (96%: 1800 ml)
was added thereto, followed by stirring in a water bath at
80.degree. C. After a homogenous (clear) solution was obtained, the
solution was stirred at 60.degree. C. After a while, crystals began
to precipitate, when the temperature of the water bath was brought
to 25.degree. C. over about 1.5 hours, followed by slow stirring
for 20 hours. Crystals that precipitated were collected by
filtration, washed with 2-propanol, and dried under reduced
pressure at 70.degree. C., to thereby yield 56.3 g of the title
compound as pale yellow crystals (yield: 82.7%).
[0069] .sup.1H-NMR(400 MHz, 0.1N NaOD).delta.: 0.57-0.70(3H, m),
0.81-0.85(1H, m), 1.40-1.64(2H, m), 3.13(1H, t, J=4.39 Hz),
3.46(1H, dd, J=10.5, 24.6 Hz), 3.60(3H, s), 3.84(1H, dd, J=7.81,
10.3 Hz), 3.99-4.06(2H, m), 5.01(1H, dm, J=64.5 Hz), 7.66(1H, d,
J=14.1 Hz), 8.42(1H, d, J=1.95 Hz).
[0070] Elementary analysis: on the basis of
C.sub.20H.sub.21F.sub.2N.sub.3- O.sub.4.1.0HCl.1H.sub.2O
[0071] Calculated: C 52.24; H 5.26; N 9.14
[0072] Found: C 52.15; H 5.25; N 9.07
[0073] Specific rotation:
[.alpha.].sub.D.sup.22-166.5.degree.(c=0.990, H.sub.2O).
[0074] Melting point: 199-208.degree. C.
Example 3
[0075]
(-)-7-{(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic acid-difluoroboron chelate (1b):
[0076] (7S)-7-Amino-5-azaspiro[2.4]heptane dihydrochloride (615 mg;
3.32 mmol) and triethylamine (1.40 ml) in dimethylsulfoxide (5 ml)
was stirred for 20 minutes at room temperature.
6,7-Difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic acid difluoroboron chelate (1.00 g; 2.77 mmol) was added
thereto, and the resultant mixture was stirred for 20 hours at room
temperature. The reaction mixture was concentrated under reduced
pressure, and purified water (50 ml) was added thereto. The pH of
the resultant mixture was adjusted to 7.0 with aqueous 1N NaOH
solution, and the aqueous layer of the mixture was taken up with
chloroform (100 ml.times.5). The organic layer was dried over
sodium sulfate, and the solvent was evaporated. The residue was
purified through recrystallization from ethanol, to thereby yield
1.14 g of the title compound as pale yellow crystals (yield:
91%).
[0077] .sup.1H-NMR (400 MHz, CDCl.sub.3).delta.: 0.65-0.73(3H, m),
0.82-0.86(1H, m), 1.50-1.60(1H, m), 1.66-1.76(1H, m), 3.25-3.27(1H,
m), 3.45-3.58(2H, m), 3.69(3H, s), 4.00-4.03(1H, m), 4.12-4.15(1H,
m), 4.19-4.24(1H, m), 4.95(1H, dm, J=62.7 Hz), 7.91(1H, d, J=13.7
Hz), 8.85(1H, d, J=2.20 Hz).
[0078] IR(KBr disk) cm.sup.-1: 3396, 3080, 3001, 2941, 2883, 1716,
1631, 1560, 1522, 1441, 1363, 1331, 1288, 1257, 1225.
[0079] Melting point: 194-197.degree. C. (decomposed)
[0080] Elementary analysis: on the basis of
C.sub.20H.sub.20BF.sub.4N.sub.- 3O.sub.4.0.25H.sub.2O
[0081] Calculated: C 52.48; H 4.51; N 9.18
[0082] Found: C 52.33; H 4.36; N 9.01
[0083] Specific rotation:
[.alpha.].sub.D.sup.19.7=-29.3.degree.(c=1.03, DMF)
Example 4
[0084]
(-)-7-{(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic Acid (1):
[0085]
(-)-7-{(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic acid difluoroboron chelate (1.14 g; 2.52 mol) was dissolved in
80% hydrated ethanol (100 ml; prepared by mixing 4 volumes of
ethanol and one volume of water). Triethylamine (2 ml) was added
thereto and the resultant mixture was subjected to reflux for 3
hours. The solvent was evaporated, and the residue was dissolved by
the addition of concentrated HCl (5 ml) and 1N--HCl (5 ml),
followed by washing with chloroform (100 ml.times.3). The pH of the
resultant acidic solution was adjusted to 8.0 in an ice bath with
aqueous 10N NaOH solution and aqueous 1N NaOH solution, followed by
stirring for three hours at room temperature (pH after completion
of stirring=7.5). Crystals precipitated were collected by
filtration and dried under reduced pressure, to thereby yield 980
mg of a crude form of the title compound as pale yellow crystals.
The crystals were purified through recrystallization from a mixture
of 28% ammonia water and ethanol, then dried under reduced
pressure, yielding 561 mg of the title compound as yellowish white
crystals (yield: 55%).
[0086] .sup.1H-NMR (400 MHz, 0.1N-NaOD) .delta.: 0.53-0.59(2H, m),
0.62-0.66(1H, m), 0.78-0.82(1H, m), 1.38-1.60(2H, m), 3.07(1H, s),
3.39(1H, dd, J=10.3, 26.0 Hz), 3.52(3H, s), 3.72(1H, d, J=10.0 Hz),
3.89-4.00(2H, m), 4.93(1H, dm, J=64.2 Hz), 7.62(1H, d, J=14.2 Hz),
8.43(1H, s).
Example 5
[0087]
7-[(7S)-5-Aza-7-tert-butoxycarbonylaminospiro[2.4]heptan-5-yl]-6-fl-
uoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-Qui-
nolinecarboxylic Acid Difluoroboron Chelate:
[0088] To 6,7-difluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-m-
ethoxy-4-oxo-3-quinolinecarboxylic acid difluoroboron chelate (1.00
g; 2.77 mmol) in dimethylsulfoxide (5 ml),
(7S)-5-aza-7-tert-butoxycarbonyla- minospiro[2.4]heptan (706 mg;
3.32 mmol) and triethylamine (927 .mu.l) were added. The resultant
mixture was stirred at room temperature for 20 hours. The reaction
mixture was concentrated under reduced pressure, and purified water
(40 ml) was added to the residue. Crystals precipitated were washed
sequentially with purified water and a small amount of diethyl
ether. The thus-washed crystals were dissolved in chloroform (100
ml), and the resultant solution was washed with water (50
ml.times.2) and saturated brine (50 ml). The organic layer was
dried over sodium sulfate, and the solvent was evaporated. The
thus-obtained crude product was purified through recrystallization
from a mixture of n-hexane and ethanol, followed by drying under
reduced pressure, to thereby yield 1.47 g of the title compound as
pale yellow crystals (yield: 96%).
[0089] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.: 0.69-0.79(2H, m),
0.83-0.97(2H, m), 1.43-1.53(1H, m), 1.45(9H, s), 1.68-1.77(1H, m),
3.49-3.52(1H, m), 3.70(3H, s), 3.79(1H, d, J=11.5 Hz), 3.88(1H, s),
4.00-4.03(1H, m), 4.16-4.22(1H, m), 4.23-4.25(1H, m), 4.76(1H,
br.s), 4.96(1H, dm, J=62.7 Hz), 7.90(1H, d, J=13.7 Hz), 8.84(1H, d,
J=2.44 Hz).
[0090] IR(KBr disk)cm.sup.-1: 3450, 3415, 3082, 3001, 2976, 2935,
2881, 1716, 1631, 1568, 1525, 1444, 1365, 1331, 1286, 1257.
[0091] Melting point: 152-155.degree. C.
[0092] Elementary analysis: on the basis of
C.sub.25H.sub.28BF.sub.4N.sub.- 3O.sub.6
[0093] Calculated: C 54.27; H 5.10; N 7.59
[0094] Found: C 54.12; H 5.13; N 7.41
[0095] Specific rotation:
[.alpha.].sub.D.sup.19.7=-23.9.degree.(c=1.00, CHCl.sub.3)
Example 6
[0096]
7-[(7S)-5-Aza-7-tert-butoxycarbonylaminospiro[2.4]heptan-5-yl]-6-fl-
uoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-qui-
nolinecarboxylic Acid:
[0097]
7-[(7S)-5-Aza-7-tert-butoxycarbonylaminospiro-[2.4]heptan-5-yl]-6-f-
luoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-qu-
inolinecarboxylic acid difluoroboron chelate (1.47 g; 2.66 mmol)
was dissolved in 80% hydrated ethanol (50 ml). Triethylamine (2 ml)
was added thereto, and the resultant mixture was subjected to
reflux for three hours. The solvent was evaporated under reduced
pressure, and aqueous 10% citric acid solution (50 ml) was added to
the residue. The mixture was extracted with chloroform (100
ml.times.2). The organic layer was washed with saturated brine (50
ml), and then dried over sodium sulfate, thereby removing the
solvent. The residue was purified through recrystallization from a
mixture of n-hexane and chloroform, followed by drying under
reduced pressure, to thereby yield 1.37 g of the title compound as
pale yellow crystals (quantitative yield).
[0098] .sup.1H-NMR (400 MHz, CDCl.sub.3).delta.: 0.64-0.75(2H, m),
0.81-0.94(2H, m), 1.45(9H, s), 1.49-1.52(1H, m), 1.54-1.62(1H, m),
3.37(1H, d, J=10.5 Hz), 3.62(3H, s), 3.63-3.67(1H, m),
3.83-3.90(3H, m), 4.06-4.10(1H, m), 4.76-4.79(1H, m), 4.85(1H, dm,
J=62.7 Hz), 7.83(1H, d, J=13.5 Hz), 8.70(1H, d, J=2.20 Hz).
[0099] IR(KBr disk)cm.sup.-1: 3448, 3361, 3074, 2979, 2935, 2881,
1734, 1693, 1622, 1512, 1448, 1367, 1325, 1352, 1252.
[0100] Melting point: 167-169.degree. C.
[0101] Elementary analysis: on the basis of
C.sub.25H.sub.29BF.sub.2N.sub.- 3O.sub.6.0.5H.sub.2O
[0102] Calculated: C 58.36; H 5.88; N 8.17
[0103] Found: C 58.50; H 5.70; N 8.17
[0104] Specific rotation:
[.alpha.].sub.D.sup.19.7=-95.2.degree.(c=0.930, CHCl.sub.3)
Example 7
[0105]
(-)-7-{(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic Acid (1):
[0106]
7-[(7S)-5-Aza-7-tert-butoxycarbonylaminospiro-[2.4]heptan-5-yl]-6-f-
luoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-qu-
inolinecarboxylic acid (1.37 g; 2.66 mmol) was dissolved by the
addition of concentrated hydrochloric acid (5 ml) and 1N HCl (5 ml)
on ice. The resultant solution was washed with chloroform (100
ml.times.3). The pH of the resultant acidic solution was adjusted
to 11.0 in an ice bath with aqueous 10N NaOH solution.
Subsequently, the pH of the obtained basic solution was adjusted to
7.4 with concentrated HCl and 1N HCl, followed by stirring for
three hours at room temperature (pH after completion of
stirring=7.4). Crystals precipitated were collected by filtration
and dried under reduced pressure, to thereby yield 1.01 g of a
crude form of the title compound as pale yellow crystals. The
crystals were purified through recrystallization from a mixture of
28% ammonia water and ethanol, yielding 351 mg of the title
compound as yellowish white crystals (yield: 33%).
[0107] .sup.1H-NMR(400 MHz, 0.1N-NaOD).delta.: 0.53-0.59(2H, m),
0.62-0.66(1H, m), 0.78-0.82(1H, m), 1.38-1.60(2H, m), 3.07(1H, s),
3.39(1H, dd, J=10.3, 26.0 Hz), 3.52(3H, s), 3.72(1H, d, J=10.0 Hz),
3.89-4.00(2H, m), 4.93(1H, dm, J=64.2 Hz), 7.62(1H, d, J=14.2 Hz),
8.43(1H, s).
Referential Example 7
[0108] Methanesulfonic Acid Salt of
(-)-7-{(7S)-7-amino-5-azaspiro[2.4]hep- tan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-metho-
xy-4-oxo-3-quinolinecarboxylic Acid:
[0109]
(-)-7-{(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl}-6-fluoro-1-[(1R,
2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbox-
ylic acid (1a) (2.51 g) was suspended in ethanol (20 ml).
Methanesulfonic acid (1.2 equivalents) was added thereto, and the
resultant mixture was stirred for five minutes at room temperature.
Subsequently, diethyl ether (80 ml) was added thereto. Crystals
precipitated were washed with diethyl ether, and collected through
filtration (2.01g, 94%).
[0110] The above-obtained crude crystals of methanesulfonic acid
salt (900 mg) was dissolved in hot isopropanol (100 ml), and the
solution was concentrated under heating until the volume of the
entire solution became 40 ml. The concentrate was allowed to cool
at room temperature, and crystals precipitated were collected
through filtration, followed by washing with isopropanol, thereby
yielding 720 mg of the title compound (yield: 80%).
[0111] Melting point: 257-258.degree. C.
[0112] .sup.1H-NMR(400 MHz, 0.1N-NaOD).delta.: 0.58-0.72(3H, m),
0.80-0.90(1H, m), 1.40-1.62(2H, m), 2.82(3H, s), 3.10-3.12(1H, m),
3.41-3.49(2H, m), 3.58(3H, s), 3.81(1H, dd, J=2.44, 9.77 Hz),
4.85-4.93, 5.04-5.07(each 0.5H, m), 7.65(1H, d, J=14.16 Hz),
8.42(1H, s).
Test Example 1
Confirmation of the crystal morphology of compound (1))
[0113] (1) FIG. 1 shows the results of powder X-ray diffractometry
of compound (1) (by means of an X'pert powder X-ray diffraction
apparatus, product of Philips), and FIG. 2 shows the IR spectrum of
compound (1) (obtained using model FT-720, FT-IR, product of
HORIBA). Thermal analysis of compound (1) revealed that the weight
loss was 4.2% by weight, which was in agreement with the
theoretical value (3.9%) of monohydrate.
[0114] (2) Quantitative analysis by the Karl Fischer's method
revealed that the water content of compound (1) is 4.11%, which is
in agreement with the result of thermal analysis.
Test Example 2
[0115] Moisture absorption/desorption of compound (1) was
investigated by using samples each weighing approximately 10 mg and
a moisture absorption analyzer manufactured by VTI (model SGA-100).
The measurement was performed at 25.degree. C., and the relative
humidity was changed in the range of 5% to 95% at intervals of 5%
or 10%. When the weight change of a sample is 0.03% or less within
30 minutes, the sample is considered to be in a state of
equilibrium, and in this test, the longest equilibrium time was set
to be 180 minutes. The weight change of each sample at different
relative humidities was determined. As a result, as shown in FIG.
3, compound (1) was found to be stable, neither absorbing or
desorbing moisture within the relative humidity range of 5-95%
RH.
Test Example 3
[0116] Acid addition salts of compound (1a) (methanesulfonic acid
salt, p-toluenesulfonic acid salts, citric acid salt, and malic
acid salt) were prepared, and their stability under various levels
of humidity was evaluated. All the tested salts showed a tendency
toward moisture absorption under high-humidity conditions. In the
meantime, although attempts were made to prepare an acetic acid
salt and a lactic acid salt of compound (1a), no salt was
formed.
Test Example 4
[0117] Solubility of compound (1) in water was investigated.
Compound (1) was found to have a high solubility in water; i.e.,
100 mg/mL or more.
Test Example 5
[0118] Compound (1) (1.5 mg) was stored for one week under the
following conditions: (1) in a sealed bottle at 70.degree. C., (2)
in an open-air state at 50.degree. C., 75% RH (NaCl), or (3)
irradiation with light at 100,000 lx.multidot.h (2,500 lx.times.40
h). Subsequently, the residual amount of compound (1) was
quantitatively determined by means of liquid chromatography.
Results are as follows: Compound (1) remained stable, not
undergoing any decomposition, even when exposed to light
irradiation. Moreover, the stability of compound (1) when exposed
to light was superior to that of compound No. 26bb disclosed in
Japanese Patent No. 2714597.
Test Example 6
[0119] Slc:ddY mice (male; 3 weeks old) were used in groups of ten.
Compound (1) was dissolved in distilled water in order to prepare
injections, and the resultant solution was cisternally administered
in a volume of 5 .mu.g/mouse. To the members of the group where
compound (1) and biphenylacetic acid were used in combination,
biphenylacetic acid (400 mg/kg) was perorally administered first,
and 30 minutes following the administration, compound (1) was
cisternally administered in a manner similar to that employed for
the single use of compound (1).
[0120] The results are as follows: In both cases of solo
administration of compound (1) and combined administration of
compound (1) and biphenylacetic acid, compound (1) caused neither
spasm nor death and was proven to have very weak central toxicity.
Thus, compound (1) is a very safe compound.
[0121] In contrast, administration of comparative compound A at the
same dose induced spasm in two mice out of ten. Also, there was one
death among the ten mice. Moreover, in the case of combined
administration with biphenylacetic acid as described above, there
were four spasm cases and two deaths out of 10 mice. 9
Test Example 7
[0122] Groups of young beagles (male; 3-4 months old), each group
consisting of 3 dogs, were used in the test. Compound (1) was
perorally administered to each dog for eight days. Thereafter,
important diarthroses were pathologically examined. Results:
Members of the groups to which compound No. 26bb disclosed in
Japanese Patent No. 2714597 was administered at high doses of 14.1
mg/kg or more showed formation of blebs or erosions in arthrodial
cartilage, whereas in the compound (1) administration groups (7.5
mg/kg, 15 mg/kg, and 30 mg/kg), formation of blebs or erosions was
not at all observed. Thus, articular toxicity of compound (1) is
quite weak and insignificant, proving that compound (1) is a very
safe compound.
Test Example 8
[0123] Groups of Balb/c mice (female; 5 weeks old), each group
consisting of 5-6 mice, were used in the test. After compound (1)
was intravenously administered to each mouse, the mouse was exposed
to long-wavelength UV light (UV-A) (20 J/cm.sup.2) for four hours.
Thereafter, the auricle was visually observed for 96 hours.
Subsequently the mouse was sacrificed for examination of the
tissue. In the groups where compound (1) was administered at (100
mg/kg), no abnormality was observed either during visual
observation or at the time of tissue examination. Thus, compound
(1) is a very safe compound, being free from phototoxicity, which
is often observed with quinolone-based antibacterial agents.
Test Example 9
[0124] (1) Therapeutic effect on mouse pneumonia model by use of
pneumococcus of low penicillin sensitivity:
[0125] Groups of CBA/J mice, each group consisting of 5 mice, were
used in the test. The mice were nasally infected with pneumococcus
SPI-13 at 5.3.times.10.sup.6 CFU/mouse. Compound (1) was
subcutaneously administered to each mouse at doses of 7.5 mg/kg, 15
mg/kg, or 30 mg/kg, for three consecutive days from the day
following infection, twice a day at an interval of 6 hours. The
efficacy of compound (1) was assessed by counting the number of the
intrapulmonary bacteria on the day following the final
administration. Results: At a dose of 30 mg/kg or 15 mg/kg,
compound (1) reduced the bacterial count to below the detection
limit, and at a dose of 7.5 mg/kg, reduced the bacterial count to
approximately half that of the control.
[0126] (2) Infection-preventing effect on mouse sepsis model.
[0127] Groups of Slc:ddY mice, each group consisting of 7 mice,
were used in the test. The mice were intraperitoneally inoculated
with methicillin-resistant Staphylococcus aureus (MRSA) strain 7866
(1.07.times.10.sup.8 CFU/mouse) or E. coli strain E77156
(8.08.times.10.sup.7 CFU/mouse). Compound (1) was given as a single
injection into the tail vein of each mouse immediately after
infection. On the basis of the survival count on day 7 after
infection, 50% efficacy was calculated using the probit method, to
thereby evaluate the efficacy. Results: The 50% efficacy of
compound (1) against MRSA strain 7866 was found to be 3.34 mg/kg,
and the same efficacy against E. coli strain E77156 was found to be
0.57 mg/kg.
[0128] From (1) and (2) above, it can be concluded that compound
(1) has excellent preventive and therapeutic effects against
different infectious diseases when tested in vivo.
Test Example 10
Antibacterial Activity
[0129] Antibacterial activity was investigated by comparing
compound (1) with comparative compounds B and C (see next page).
This test was performed according to the standard method
recommended by Japanese Society of Chemotherapy. The test results
are shown in Table 1.
1TABLE 1 Antibacterial Activity MIC (.mu.g/mL) Comparative
Comparative Compound (1) Compound b Compound C E. coli, NIHJ
.ltoreq.0.003 0.006 0.025 Pr. vulgaris, 08601 0.012 0.05 0.05 Ser.
marcescens, 10100 0.05 0.20 0.20 Ps. aeruginosa, 32104 0.20 0.39
0.78 Ps. aeruginosa, 32121 0.05 0.20 0.39 S. aureus, 209P 0.006
0.025 0.05 S. epidermidis, 56500 0.05 0.10 0.20 Str. faecalis, ATCC
19433 0.10 0.20 0.39 10 11
[0130] The compounds of the present invention are endowed with
excellent antibacterial activity and safety, and also are very
stable against light or humidity, thereby finding utility as
antibacterial agents.
* * * * *